Wire Stories
-
13.0KOutsource Accelerator Calls for Outsourcing Impact Review 2024 Entries
MANILA, Philippines–(BUSINESS WIRE)–#CSR—Outsource Accelerator, the premier source of independent information, advisory, and advocacy for the outsourcing industry, is excited to announce the...
-
15.4KBionova Scientific, U.S. biologics CDMO of the Asahi Kasei Group, to establish a facility in Texas and launch plasmid DNA business
TOKYO & NEW YORK & DÜSSELDORF, Germany–(BUSINESS WIRE)–Asahi Kasei Medical’s U.S. subsidiary Bionova Scientific, a full-service biologics CDMO, has decided to launch...
-
18.1KAKM Achieves Successful Proof of Concept for eFuse in High Voltage 800 V Automotive Applications
Door opener for compact, fast and reliable protection of e.g., on-board chargers or DC/DC converters for electric vehicles TOKYO & NEW YORK...
-
15.1KEnergy Vault Executes EPC and O&M Contract with ACEN Australia for 200 MW/400 MWh of Battery Energy Storage Deployments
ACEN Australia and Energy Vault to begin deployment of two battery energy storage systems (BESS), with a total capacity of 200 MW/400...
-
13.7KDebiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family
Debiopharm granted exclusive global rights to use Genome & Company’s antibodies to develop potential first-in-class ADCs integrating Debiopharm’s Multilink™ technology. LAUSANNE, Switzerland...
-
16.4KInocras and Massive Bio Forge Groundbreaking Alliance to Revolutionize Cancer Care with Whole-Genome Insights and Clinical Trial Matching
SAN DIEGO–(BUSINESS WIRE)–#WGS–Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have...
-
15.8KInternational Energy Forum Report Details EV Copper Hurdles
Generation Mining Hosting Fireside Chat with Report Co-Author TORONTO–(BUSINESS WIRE)–$genm #copper–Generation Mining Limited (TSX:GENM, OTCQB: GENMF) welcomes the recent report by the...
-
24.7KTakeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
– Phase 2b Trial Demonstrated Statistically Significant and Clinically Meaningful Improvements Across Primary and all Secondary Endpoints up to 8 Weeks –...
-
14.9KShining Bright atop Taipei 101, GIGABYTE Redefines AI Evolution Accelerated by Next-Generation Computing at COMPUTEX
TAIPEI–(BUSINESS WIRE)–#ACCEVOLUTION–Renowned globally for its research and development capabilities, GIGABYTE Technology will exhibit its products and solutions at COMPUTEX from June 4...
-
17.3KSummit Raises $200 Million; Also Expands License Territories for Ivonescimab
$200 Million in Net Proceeds Raised at Premium to Previous Closing Price In Separate Transaction, Summit Expanded License Territories for Ivonescimab in...
To Top